**Author:** Dr. JJ Arellano

**Author:** Jarrad G.

**Author:** Dr. JJ Arellano

Compass Pathways announced its second positive Phase 3 clinical trial for psilocybin-assisted therapy this month, but the modest treatment effect size has industry observers questioning what FDA approval standards will demand from psychedelic medicines.

The psychedelic medicine movement reached a critical inflection point this month when the Multidisciplinary Association for Psychedelic Studies (MAPS) released its comprehensive Policy Guidebook, strategically timed for what promises to be a transformative election year for treat

**New research, safer protocols, and growing clinical acceptance are transforming how the medical community views ibogaine therapy for addiction, PTSD, and treatment-resistant depression.**

**Author:** Dr. JJ Arellano, Medical Director, MindScape Retreat

**Published:** February 18, 2026

**Category:** Research & Science

**Category:** Research & Science

In a move that signals the psychedelic therapy movement is reaching mainstream medicine, outgoing New Jersey Governor Phil Murphy signed SB 2283 into law, establishing a two-year psilocybin pilot program across three hospitals in the state. The program comes with $6 million in fu

The momentum behind ibogaine research in the United States just took another significant leap forward. In a single week, three new states introduced legislation aimed at funding ibogaine research, bringing the total number of states with active ibogaine-related bills to at least

A groundbreaking study published this month in Nature's npj Mental Health Research has done something that decades of ibogaine advocacy could not: it has given the scientific community a rigorous, qualitative map of what actually happens inside the ibogaine experience and why it

Something remarkable happened in Texas at the start of 2026, and most people in the addiction treatment world haven't caught up yet. The Texas Health and Human Services Commission awarded fifty million dollars to UTHealth Houston and the University of Texas Medical Branch at Galv

**Date:** February 13, 2026

**Date:** February 13, 2026

**Date:** February 13, 2026